Thalidomide maker 'ignored birth defects for years'

July 27, 2012 by Amy Coopes in Medications

The German makers of thalidomide were warned of birth defects years before it was withdrawn and Australian distributors used pregnant women as the world's first test subjects, court papers alleged Friday.

Affidavits sworn in the lawsuit of an Australian woman born without limbs after her mother took thalidomide claimed that the drug's maker Grunenthal ignored and covered up claims that it caused birth defects dating back to 1959.

Thalidomide was not withdrawn from sale until late 1961, but excerpts of internal company correspondence filed in the Supreme Court of Victoria alleged doctors first warned of serious deformities more than two years earlier.

An estimated 10,000 children worldwide were born with defects after their mothers took thalidomide, which was marketed as a morning sickness drug and sold in nearly 50 countries.

The correspondence was obtained in an Australian class action involving up to 100 thalidomide victims, sections of which were published online Friday in two lengthy affidavits sworn by counsel leading the case, Michael Magazanik.

Magazanik said the previously secret documents revealed repeated warnings to Grunenthal from doctors and distributors from as far afield as Sri Lanka and Lebanon.

He said the documents also showed thalidomide was never tested on gestating animals before it went on sale.

Instead, the first clinical trials in the world were conducted in Australia in 1960 and used "pregnant women rather than laboratory animals as experimental subjects", he alleged.

At that time doctors were already allegedly warning Grunenthal that their drug had caused birth defects, and throughout 1960-61 hospitals and pharmacists were returning their entire thalidomide stocks or refusing to buy or supply it.

Some six months before it was formally declared unsafe and removed from sale Grunenthal's own staff were already refusing to use thalidomide, fearing its side-effects, Magazanik's affidavit claimed.

As many as 10 Grunenthal staff had children with birth defects after taking thalidomide between 1959-61, it said, with a similar number of deformities among children born to employees at its British partner Distillers.

In-house lawyers warned the company repeatedly in 1961 that it had "behaved improperly in failing to provide adequate warnings to doctors and consumers", had been negligent and was at "great risk in legal proceedings", it added.

According to the documents, Grunenthal misled and failed to inform distributors in Britain and Germany about the extent of problems and deliberately withheld that information from the US Food and Drug Authority.

The Australian case, which is yet to go to trial, is being led by wheelchair-bound Lynette Rowe, 50, who was born without arms and legs after her mother took thalidomide during pregnancy.

Distillers, which is now part of Diageo, settled out of court with Rowe this month and agreed to negotiate with others in her class action, but Grunenthal has denied wrongdoing and vowed to "fully defend" any legal action.

"Grunenthal maintains that its actions were consistent with the state of scientific knowledge and the prevailing standards for pre-marketing and testing of the pharmaceutical industry in the 1950s," it said of Rowe's case.

(c) 2012 AFP

5 /5 (2 votes)  

Rank 5 /5 (2 votes)
Related Stories
Relevant PhysicsForums posts

More news stories

Merck ends development of Parkinson's disease drug

(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.

Medications created May 23, 2013 | popularity 1 / 5 (1) | comments 0

J&J expects 10-plus new drug applications by 2017

(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...

Medications created May 23, 2013 | popularity 5 / 5 (1) | comments 0

Experts favor US approval of Merck sleeping pill (Update)

An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Glaxo, US partnering to develop new antibiotics

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine

The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...

Medications created May 22, 2013 | popularity not rated yet | comments 0


Engineered cytomegalovirus protects monkeys from HIV equivalent

(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...

Researchers identify first drug targets in childhood genetic tumor disorder

Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...

Hormone levels may provide key to understanding psychological disorders in women

Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.

Going live: Immune cell activation in multiple sclerosis

Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...

Driving and hands-free talking lead to spike in errors, study shows

Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.

Help at hand for people with schizophrenia

How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.